| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785895 | Cancer Treatment Reviews | 2018 | 10 Pages |
Abstract
In this review we describe the active or ongoing clinical trials involving Programmed Death Ligand 1 (PD-L1), Programmed Death receptor 1 (PD-1) and Cytotoxic-T Lymphocyte Antigen 4 (CTLA 4) inhibitors in urothelial carcinoma focusing our attention on the developing new immune-agents and combination strategies with immune-checkpoint inhibitors.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Francesco Massari, Vincenzo Di Nunno, Marta Cubelli, Matteo Santoni, Michelangelo Fiorentino, Rodolfo Montironi, Liang Cheng, Anto Lopez-Beltran, Nicola Battelli, Andrea Ardizzoni,